Karyopharm stock drops af­ter in­hibitor's PhI da­ta show low­er dose not as ef­fec­tive: #AACR23

Karyopharm Ther­a­peu­tics shared up­dat­ed Phase I da­ta for its oral XPO1 in­hibitor, which is be­ing test­ed as a treat­ment for myelofi­bro­sis in com­bi­na­tion with rux­oli­tinib …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER